Identification
- Generic Name
- Talactoferrin alfa
- DrugBank Accession Number
- DB05426
- Background
Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Talactoferrin alfa
- Talactoferrin alpha
- External IDs
- LF-00
- LF00
Pharmacology
- Indication
Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Oral talactoferrin stimulated the production of the immunostimulatory cytokine IL-18 in mice, increasing IL-18 levels both in the gut and in systemic circulation. Oral talactoferrin was also shown to stimulate the activity of NK cells and to increase the production and activity of key circulating immune cells.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Talactoferrin alfa is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Animal Proteins, Dietary
- Antineoplastic Agents
- Carbohydrates
- Carrier Proteins
- Dietary Proteins
- Endopeptidases
- Enzymes
- Enzymes and Coenzymes
- Globulins
- Glycoconjugates
- Glycoproteins
- Hydrolases
- Iron-Binding Proteins
- Lactoglobulins
- Metalloproteins
- Milk Proteins
- Peptide Hydrolases
- Proteins
- Recombinant Proteins
- Serine Endopeptidases
- Serine Proteases
- Transferrins
- Whey Proteins
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7A055A9QRR
- CAS number
- 308240-58-6
References
- General References
- Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, Armstrong DG, Reese A, Yankee EW, Veves A: Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. [Article]
- External Links
- PubChem Compound
- 192716
- PubChem Substance
- 175427001
- ChemSpider
- 167235
- 1425932
- ZINC
- ZINC000150376965
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Non-Small Cell Lung Cancer (NSCLC) 1 3 Unknown Status Treatment Non-Small Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Severe Sepsis 1 2, 3 Suspended Treatment Severe Sepsis 1 1, 2 Unknown Status Prevention Hospital Acquired Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at November 18, 2007 18:24 / Updated at February 21, 2021 18:51